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While not essential for normal thrombosis and hemostasis, platelet-
derived VWF fosters ischemic stroke injury in mice. 
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Key points:  
 
1. Platelet-derived VWF alone is sufficient for full ischemic stroke injury in mice, and 
relies on a GPIb-dependent mechanism  
 
2. Platelet-derived VWF does not significantly contribute to normal thrombosis and 
hemostasis in mice 
 
 
Abstract 
 
Von Willebrand factor (VWF) is a key hemostatic protein synthesized in both 
endothelial cells and megakaryocytes. Megakaryocyte-derived VWF is stored in α-
granules of platelets and is enriched in hyperactive ‘ultra-large’ VWF multimers. To 
elucidate the specific contribution of platelet VWF in hemostasis and thrombosis we 
performed crossed bone marrow transplantations between C57BL/6J and Vwf-/- mice 
to generate chimeric mice. Chimeric mice specifically lacking platelet VWF showed 
normal tail bleeding and carotid artery thrombosis, similar to wild type mice. 
Chimeric mice with VWF present only in platelets were not able to support normal 
thrombosis and hemostasis. However, using a mouse model of transient middle 
cerebral artery occlusion, we observed that cerebral infarct sizes and fibrin(ogen) 
deposition in chimeric mice with only platelet VWF were significantly increased 
compared with Vwf-/- mice (p < 0.01). Blocking of the platelet VWF-GPIb interaction 
abrogated this platelet VWF-mediated injury. These data suggest that whereas 
platelet-derived VWF does not play a crucial role in hemostasis and arterial 
thrombosis, it aggravates thrombo-inflammatory diseases such as stroke via a GPIb-
dependent mechanism. 
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Introduction 
 
Von Willebrand factor (VWF) is an adhesive multimeric glycoprotein that is crucial 
for normal hemostasis. The best-known functions of VWF are facilitating platelet 
adhesion at sites of vascular injury and protecting clotting factor VIII against early 
degradation in the circulation. Consequently, absence or dysfunction of VWF results 
in bleeding symptoms as observed in patients with von Willebrand disease (VWD).1 
Intriguingly, it has become clear that VWF is also implicated in various non-
hemostatic processes, such as tumor metastasis, inflammation and angiogenesis.2 In 
particular, the pathophysiological role of VWF in ischemic stroke has recently gained 
increased attention.3-7 
Biosynthesis of VWF is restricted to endothelial cells (ECs) and megakaryocytes. 
Endothelial VWF is constitutively secreted into plasma and subendothelium or stored 
as ‘ultra-large’ VWF (UL-VWF) multimers in Weibel-Palade bodies. VWF produced 
in megakaryocytes ends up as UL-VWF in the α-granules of platelets. VWF present 
in endothelial and platelet storage organelles is secreted in a regulated process in 
response to stimulation by secretagogues. Platelets contain a significant amount of 
VWF, accounting for 15-20% of the total amount of circulating VWF. Interestingly, 
an increasing body of evidence shows that platelet VWF differs in various 
biochemical aspects from endothelial VWF.8 Williams et al. showed that, in 
comparison with plasma VWF, platelet VWF binds more efficiently to glycoprotein 
(GP)IIb/IIIa and heparin whereas it is less capable of binding to GPIb.9 Divergent 
glycosylation profiles could explain these differences. Indeed, platelet VWF exists as 
a distinct glycoform, characterized by a significantly reduced degree of N-linked 
sialylation and by the absence of expression of AB blood group determinants.8,10 This 
differential glycosylation also renders platelet VWF more resistant to ADAMTS13 
proteolysis.10 With platelet VWF being enriched in UL-VWF, this resistance to 
ADAMTS13 cleavage could become particularly relevant in settings where local 
accumulation of UL-VWF is detrimental, like cerebral or myocardial 
ischemia/reperfusion injury.6,11,12 Given variable platelet VWF antigen and activity 
levels between individuals, it is important to understand the biological activity of this 
specific pool of VWF. Only a few studies have tried to dissect the different 
(patho)physiological roles of platelet and plasma VWF. Although experimental 
evidence shows that platelet VWF indeed contributes to initial platelet adhesion to 
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collagen at sites of vascular injury13-15 in vivo data on the role of platelet VWF in 
thrombosis is limited. The role of VWF from platelets in ischemic stroke has never 
been investigated. In the present study, we found that plasma VWF but not platelet 
VWF is needed for normal hemostasis and carotid artery thrombus formation whereas 
platelet VWF by itself is able to mediate ischemic brain injury via a GPIb-dependent 
mechanism, shedding new light on the role of platelet VWF in thrombo-inflammatory 
disease. 
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Methods 
 
Mice 
Vwf-/- (VWF KO)16 and littermate wild-type (WT) C57BL/6J mice were used. All 
animal experiments were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee of the KU Leuven (Belgium). 
 
Bone marrow transplantation 
Bone marrow cells were collected from the femur and tibia of six to ten week old 
donor mice. The mononuclear cell population (MNC) was isolated using ficoll 
gradient centrifugation (Ficoll-PaqueTM Premium 1.084; GE Healthcare, Waukesha, 
IL). Six to eight week old recipient VWF KO and WT mice were conditioned for 
cellular transplantation with a single lethal dose of 1100 cGy total body irradiation 
using a dual linear energy accelerator (Clinac DHX, 6MV; Varian Medical Systems, 
CA). Twenty-four hours after irradiation, 10 x 106 MNC dissolved in 250μl sterile 
phosphate buffered saline (PBS) were infused by intravenous injection in irradiated 
recipient mice. Three to four weeks after transplantation full chimerism was 
confirmed via flow cytometry.  
 
Blood collection   
Animals were anesthetized using 5% isoflurane (Nicholas Piramal Limited, London, 
UK) in 100% O2. Blood was collected by retro-orbital puncture on 0.5M EDTA (1 
volume to 40 volumes of blood) or 3.8% trisodium citrate (1 volume to 6 volumes of 
blood). EDTA-treated blood was used to determine platelet counts using the Hemavet 
950FS Multi-species Hematology system (Drew Scientific, Oxford, CT). Platelet-rich 
plasma (PRP) was prepared from citrated blood by centrifugation at 325g for 5 
minutes at room temperature (RT) and immediately used for flow cytometric analysis. 
Platelet-poor plasma (PPP) was prepared from citrated blood by centrifugation at 
4300g for 6 minutes at 4°C and stored at -20°C for further analysis.  
Flow cytometry 
Three to four weeks after transplantation, citrated PRP was prepared from chimeric 
and control mice. After fixation, permeabilized platelets were incubated with a 
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primary rabbit anti-human VWF antibody (1:100; Dako, Glostrup, Denmark) and a 
secondary FITC-conjugated swine anti-rabbit antibody (1:40; Dako) as described in 
supplemental Methods (available on the Blood website). To quantify the relative 
amount of VWF-positive platelets, a standard curve (0%, 25%, 50%, 75%, and 100% 
VWF-positive platelets) was made by combining PRP from WT and VWF KO mice. 
Results were expressed as percentage of WT values. To identify the platelet 
population, platelets were stained with rat anti-mouse CD41 antibody conjugated with 
PE (1:50; eBioscience, San Diego, CA). Expression of CD41 and intracellular platelet 
VWF was determined using a Beckman Coulter EPICS XL-MCL flow cytometer and 
analyzed with the WinMDI 2.9 free FACS analysis software. 
 
VWF and FVIII analysis 
VWF antigen levels in plasma were determined using an in-house developed ELISA 
assay. A detailed description of this assay is provided in supplemental Methods. FVIII 
activity (FVIII:C) in mouse plasma was determined using the COATEST® SP4 FVIII 
(Chromogenix, Molndal, Sweden) according to the manufacturer’s protocol. Pooled 
plasma from 10 to 20 WT mice was used as a reference (100%) and results were 
expressed as percentage of WT values.  
Tail clip bleeding time assay 
Tail clip bleeding times were assessed as described.17 Five to six weeks after 
transplantation, mice were anesthetized with intraperitoneal injection of pentobarbital 
(60 mg/ml; Nembutal, Ceva Santé Animale, Brussels, Belgium). Immediately after 
removing 5mm of the tail tip using a surgical scalpel, the tail was immersed in 0.9% 
NaCl pre-warmed at 37°C. The time until blood loss ceased was monitored. The 
experiment was stopped when bleeding did not stop within 600 seconds. 
 
FeCl3-induced carotid artery thrombosis model 
Eight to ten weeks after transplantation, mice were anesthetized using 2.5% isoflurane 
in 100% O2. The right carotid artery was subsequently exposed and a doppler flow 
probe (Transonic TS420 perivascular flow meter module; AD Instruments, Oxford, 
UK) was positioned around the artery to monitor blood flow via a laser doppler 
perfusion monitor (PeriFlux System 5000; Perimed AB, Järfälla-Stockholm, Sweden) 
coupled to a PowerLab 8/35 data acquisition unit (AD Instruments) using LabChart 
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v8.0.5 software (AD Instruments). Arterial thrombosis was induced by applying a 
piece of WhatmanTM filter paper (1 x 1 mm; GE Healthcare) saturated in 12% FeCl3 
solution, for 3 minutes downstream of the flow probe. The time to occlusion (TTO) 
was recorded. If the TTO exceeded 50 minutes, the experiment was ended.  
 
Transient middle cerebral artery occlusion 
Focal cerebral ischemia was induced 8 to 10 weeks after transplantation by 60 
minutes transient middle cerebral artery occlusion (tMCAO) as described.5 To block 
the VWF-GPIb interaction, 100 μg rat anti-mouse GPIbα (p0p/B) Fab18 or rat IgG Fab 
control was injected intravenously 5 minutes after inducing reperfusion of the right 
middle cerebral artery. All stroke experiments were conducted according to the 
recommendations for research in experimental stroke studies and the current ARRIVE 
guidelines (http://www.nc3rs.org/ARRIVE). Animals were randomly assigned to the 
operators by independent persons not involved in data acquisition and analysis. 
Surgeries and evaluation of all readout parameters were performed while being 
blinded to the experimental groups. 
 
Determination of infarct size  
Assessment of infarct size was performed 24 hours after induction of cerebral 
ischemia as described.5 After sacrificing the animal, the brain was removed and 
sectioned in three consecutive 2 mm thick sections. Sections were stained with 2% 
2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich) in PBS and fixated. 
Pictures were taken and the infarct volume was calculated via planimetry (ImageJ 
Software, National Institutes of Health, USA). 
Western blot analysis 
Western blot for fibrin/fibrinogen was performed as previously described.5 TTC-
stained coronal brain sections of 1 mouse were separated in ipsi- and contralateral 
parts, pooled, and homogenized. Immunoreactivity for fibrin(ogen) [(anti-fibrin(ogen) 
pAb 1:500; Acris Antibodies GmbH, Herford, Germany] was detected by Western 
blot analysis and quantified by densitometry using ImageJ sofware. Actin served as 
loading control. The amount of fibrin(ogen) was normalized to the actin signal. The 
ratio of the normalized ipsilateral fibrin band density relative to the normalized band 
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density of contralateral fibrin served as a measurement for relative fibrin deposition. 
A detailed description of this assay is provided in supplemental Methods. 
 
Statistics 
Data are expressed as mean ± SEM. For statistical analysis, the Prism Version 6.0 
software (GraphPad Software; La Jolla, CA) was used. Statistical analysis was 
conducted using one-way ANOVA followed by the Tukey’s multiple comparison post 
hoc test to assess variance between FVIII:C levels, cerebral infarct sizes and 
fibrinogen deposition in different experimental groups. The Kruskal-Wallis test 
followed by Dunn’s multiple comparison post hoc test was used to compare plasma 
VWF antigen levels, tail clip bleeding times and arterial occlusion times. P values less 
than .05 were considered statistically significant.  
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Results 
Generation of chimeric mice expressing VWF only in megakaryocytes or 
endothelial cells 
To determine the contribution of platelet VWF in hemostasis and thrombosis, we 
generated chimeric mice that produce VWF only in megakaryocytes or endothelial 
cells, respectively. Mononuclear cells (MNC) were isolated from WT donor mice and 
transplanted into lethally irradiated VWF KO acceptor mice, resulting in chimeric 
mice with only platelet VWF (VWF PLT, Figure 1A). By transplanting VWF KO 
MNC into WT acceptor mice, chimeric mice that specifically lack VWF in platelets 
were obtained (VWF EC, figure 1B). No difference in platelet count between 
chimeric mice and VWF KO and WT mice was observed (data not shown). To 
confirm successful transplantation, the relative amount of VWF-containing platelets 
was determined via flow cytometry (Figure 1C). As in VWF KO mice, no VWF-
positive platelets were detected in VWF EC chimeric mice. On the other hand, the 
relative amount of VWF-positive platelets in VWF PLT chimeric mice (98.44 ± 
1.87%, n = 18) was similar to WT mice (99.94 ± 1.31%, n = 12) (Figure 1C).  
Absence of VWF-positive platelets in VWF EC chimeric mice confirms previous 
findings that endocytosis of VWF from plasma to platelet α-granules does not 
occur.15,19 As expected, platelets do not seem to release significant amounts of VWF 
into the circulation under normal conditions (Figure 1D). Indeed, normal plasma 
levels of VWF antigen were found in WT mice (99.9 ± 7.1%, n = 16) and VWF EC 
chimeric mice (106.3 ± 9.3%, n = 8) whereas no detectable levels of VWF were 
observed in plasma of VWF KO mice (n = 14) and most VWF PLT chimeric mice (n 
= 21). However, in some (7 out 21) VWF PLT chimeric mice trace amounts of VWF 
were observed, which could account for the slightly (but non-significantly) increased 
FVIII activity (14.3 ± 1%, n = 16) compared to VWF KO mice (6.3 ± 0.4%, n = 12) 
(Figure 1E). FVIII activity levels in the VWF EC chimeric mice (83.6 ± 3.1%, n = 10) 
were slightly decreased when compared to WT mice (100 ± 4.6%, n = 12) but 
remained in the normal range (Figure 1E). These data further confirm the notion that 
plasma VWF mainly originates from endothelial cells and that no platelet VWF is 
constitutively secreted into the circulation under normal circumstances.  
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Plasma but not platelet VWF is the major determinant for normal hemostasis 
To unravel the specific role of platelet VWF in hemostasis, we used our chimeric 
mice in a tail clip bleeding assay. After removing 5 mm of the tip of the tail, the time 
needed to stop bleeding was recorded (Figure 2). As expected, most WT animals 
stopped bleeding within 3 min (100.9 ± 18.7 s, n = 15) while VWF KO mice were not 
able to control the bleeding within 10 min (> 600 s, n = 14). Interestingly, most of the 
VWF PLT chimeric mice also bled longer than 10 min (528.2 ± 38.9 s, n = 16). 
Bleeding stopped spontaneously in 3 out of 16 mice (19%). In chimeric mice that only 
produce endothelial VWF (VWF EC), bleeding times were comparable to those of 
WT mice (101.1 ± 17.3 s, n = 9). These data suggest that platelet VWF alone is not 
able to support normal hemostasis and that lack of platelet VWF does not affect 
bleeding in this model.  
 
Plasma but not platelet VWF regulates arterial thrombus formation 
Ex vivo flow chamber studies have previously shown that platelet-derived VWF plays 
a role in platelet adhesion to collagen.13-15 However, the exact role of platelet VWF in 
in vivo thrombus formation in mice has never been studied. To address this question, 
we performed a FeCl3-induced carotid artery thrombosis model (Figure 3). In WT 
mice, an occlusive thrombus was consistently formed within 10 min (9.2 ± 0.5 min, n 
= 8). In contrast, no occlusive thrombus was formed within the first 50 min in VWF 
KO mice (n = 5). Interestingly, arterial occlusion times in VWF EC chimeric mice 
(10.6 ± 0.4 min, n = 6) were similar to WT mice while no occlusive thrombi were 
formed in VWF PLT chimeric mice (n = 8). These results indicate that on the one 
hand platelet-derived VWF alone is not able to support normal thrombus formation in 
this model, and that on the other hand lack of VWF in platelets does not affect normal 
arterial thrombosis. 
 
Both endothelial cell- and platelet-derived VWF alone are able to mediate ischemic 
brain injury  
We and others showed that VWF plays a crucial role in ischemic stroke most 
probably by recruiting platelets and leukocytes in the reperfused tissue.3-5 
Interestingly, absence of ADAMTS13 further aggravates ischemic brain damage, 
suggesting a specific contribution of UL-VWF multimers in the pathophysiology of 
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stroke.4,12,20 Given the abundance of UL-VWF multimers in α-granules of platelets, 
we explored the specific contribution of platelet VWF in ischemic brain injury. After 
60 minutes of focal cerebral ischemia, blood flow in the middle cerebral artery was 
restored to allow reperfusion of the ischemic territory. Twenty-four hours after 
induction of ischemia, cerebral infarction sizes were determined (Figure 4). In 
accordance with our previous studies,3,5 cerebral infarct sizes observed in VWF KO 
mice (34.4 ± 5.2 mm3, n = 12) were significantly reduced compared to WT mice (78.9 
± 10.2 mm3, n = 10). As expected, VWF EC chimeric mice developed infarcts that 
were similar in size to WT animals (76.7 ± 8.4 mm3, n = 9). Surprisingly however, 
VWF PLT chimeric mice expressing VWF only in platelets also showed infarct sizes 
that were similar to WT mice (79.6 ± 8.1 mm3, n = 16). Because cranial irradiation 
may induce persistent neuroinflammation in C57BL/6J mouse brain21,22 we tested 
lethally irradiated VWF KO mice transplanted with VWF KO MNCs to exclude any 
potential effect of irradiation on cerebral injury in our model (Figure 4C). In this 
separate set of experiments, infarct sizes were still small (18.71 ± 4.31 mm3, n = 7) 
and comparable with those observed in VWF KO mice (19.43 ± 5.49 mm3, n = 7). 
Hence, the irradiation procedure had no effect on infarct size in VWF KO animals. 
Together, these data show that the presence of either platelet VWF or plasma VWF 
alone is sufficient to cause VWF-mediated ischemic stroke injury.  
Platelet VWF-mediated ischemic brain injury is GPIbα-dependent. 
We next wanted to further elucidate the mechanism by which platelet VWF 
exacerbates ischemic stroke. The main interactions of VWF in platelet adhesion and 
thrombus formation are binding to platelet GPIb, collagen and platelet GPIIb/IIIa. 
Interestingly however, Williams and colleagues have shown that platelet-derived 
VWF binds GPIbα with lower affinity than plasma VWF.9 To test whether binding of 
platelet VWF to GPIb is important in ischemic stroke, we blocked the VWF-GPIbα 
axis using an anti-GPIbα (p0p/B) Fab fragment (Figure 5).23 Interestingly, 
administration of p0p/B significantly reduced cerebral infarct development in VWF 
PLT chimeric mice (44.8 ± 10.19 mm3, n = 8) to levels as observed in VWF KO mice 
(43.38 ± 10.02 mm3, n = 5). These were half the size of those observed in non-treated 
WT mice (92.19 ± 11.52 mm3, n = 6) or VWF PLT chimeric mice that received IgG 
control Fab (83.07 ± 3.7 mm3, n = 12). These data suggest that the detrimental effect 
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of platelet VWF in ischemic stroke is mediated by a platelet GPIbα-dependent 
mechanism. 
It is interesting to note that no cerebral hemorrhagic events were observed in all 
experimental groups after macroscopic analysis of whole brains and of 2-mm brain 
sections (data not shown), which is in line with our previous studies.3,5,23 
 
Platelet-derived VWF exacerbates ischemic brain injury by promoting intracerebral 
thrombosis 
To gain further insight on how platelet VWF promotes cerebral injury, we measured 
fibrin(ogen) deposition in the brain after stroke (Figure 6). In WT mice, the ischemic 
hemisphere contained almost four times more fibrin(ogen) than the contralateral 
hemisphere (ratio ipsilateral/contralateral of 3.69 ± 0.37, n = 9) 24 hours after stroke, 
suggesting thrombotic events occurring during the ischemia/reperfusion phase. In 
VWF KO mice, significantly less fibrin(ogen) was found in the ipsilateral hemisphere 
(only a 1.44 ± 0.17-fold increase of contralateral, n = 8). Reconstitution of the platelet 
VWF compartment in VWF KO mice (VWF PLT) again significantly increased 
cerebral fibrin(ogen) deposition in the affected hemisphere (ratio 
ipsilateral/contralateral of 2.99 ± 0.56, n = 7). Interestingly, when VWF PLT chimeric 
mice were treated with anti-GPIbα Fab, fibrin(ogen) in the ipsilateral hemispheres 
was reduced (ratio ipsilateral/contralateral of 1.28 ± 0.10, n = 5). Administration of 
control IgG Fab to VWF PLT chimeric mice did not alter fibrin(ogen) deposition in 
the brain (ratio ipsilateral/contralateral of 3.75 ± 0.34, n = 6). These data suggest a 
significant contribution of platelet-derived VWF in intracerebral fibrin(ogen) 
deposition during ischemic stroke that depends on VWF binding to GPIbα. 
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Discussion 
As a main finding of this study, we showed that platelet VWF is not essential for 
normal hemostasis and arterial thrombus formation but that this specific pool of VWF 
can contribute to ischemic brain injury via a GPIbα-dependent mechanism.  
Although normal plasma VWF levels were observed in VWF EC chimeric mice, no 
VWF was detected in their platelets. This observation confirms earlier transplantation 
studies performed in both mice15 and pigs19 and corroborates the absence of VWF in 
platelets of VWD type 3 patients after replacement therapy.24 Hence, our data further 
support the hypothesis that platelet VWF originates solely from megakaryocytes and 
is not taken up from plasma, in contrast to e.g. fibrinogen. Chimeric mice with VWF 
only in platelets did not show any significant amounts of VWF in plasma. In addition, 
no significant increase in circulating FVIII was observed. Similar observations were 
obtained in chimeric pigs.19 Interestingly, Kanaji et al.15 showed trace amounts of 
circulating VWF in chimeric mice that only have VWF in platelets. One possible 
explanation of this discrepancy could be a difference in VWF ELISA detection 
sensitivities. Alternatively, slight platelet activation can result in the release of VWF 
in the plasma.  
The contribution of platelet-derived VWF in normal hemostasis is still not totally 
clear. Case studies in humans suggested that platelet-derived VWF is beneficial for 
normalization of bleeding.25-28 Our tail clip bleeding experiments show that 
endothelial cell-derived VWF is the major determinant in the process of normal 
hemostasis. This concept is further supported by earlier observations of defective 
hemostasis in mice15 and pigs29,30 with VWF only in platelets. Furthermore, 
hydrodynamic gene transfer experiments that target the liver for VWF expression also 
show that VWF present only in plasma can correct the bleeding diathesis of VWF KO 
mice17,31. Nevertheless, we observed that a small subset (19%) of mice expressing 
VWF only in platelets had partially corrected bleeding times, suggesting that in some 
cases platelet-derived VWF is more or less able to support hemostasis. Similar results 
were obtained by Kanaji and colleagues who showed that 38% of their VWF PLT 
mice also had a partially corrected bleeding time.15 Why bleeding stopped in some of 
our VWF PLT mice remains unclear. These mice did not show higher platelet counts 
nor did they have higher levels of plasma VWF or FVIII. Although less likely, 
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differences in size and quantity of VWF in the platelet granules might contribute to 
these observations. More studies, preferably using bleeding models that more closely 
mimic clinically relevant human hemorrhage, are needed to further clarify the specific 
function of platelet VWF in bleeding.  
Platelet VWF is important for initial in vitro platelet adhesion on collagen-coated 
surfaces.15,30 To test whether this is relevant for in vivo thrombus formation, we used 
a FeCl3-induced carotid artery thrombosis model. Interestingly, mice having VWF 
only in platelets (VWF PLT) could not form occlusive thrombi, whereas chimeric 
mice with only endothelial cell-derived VWF (VWF EC) did so within 10 minutes. 
Thus, overall arterial thrombus formation does not seem to be largely dependent on 
VWF in platelets, which is in line with earlier thrombosis studies in chimeric pigs.29 
In our model, we were not able to assess initial platelet adhesion rates after carotid 
artery injury but lack of VWF in platelets seemed to slow down the rate of blood flow 
reduction compared with WT mice, an effect that was however lost in the total 
kinetics of occlusive thrombus formation in the large carotid artery. Studies using 
other thrombosis models would be helpful to further explore the specific role of 
platelet VWF in thrombus formation. 
 
Increased platelet adhesion at sites of vascular injury could be important in 
thrombotic pathologies affecting the microcirculation such as ischemic stroke. We 
and others have shown that VWF KO mice are protected from stroke.3-5 Chimeric 
mice that lack VWF in platelets (VWF EC) developed the same cerebral infarctions as 
observed in WT animals, suggesting that plasma VWF alone can mediate the VWF-
dependent ischemic brain injury. These findings are in agreement with the same large 
infarctions observed in VWF KO mice reconstituted with plasma VWF via 
hydrodynamic VWF gene transfer.5 Surprisingly, stroke lesions in VWF PLT 
chimeric mice were also similar to those seen in WT mice. Indeed, whereas VWF 
PLT chimeric mice display a phenotype similar to VWF KO animals in the tail-
clipping bleeding and carotid artery thrombosis model, this is not the case in the 
stroke model. Hence, the contribution of VWF in platelets seems to be specifically 
relevant in the setting of cerebral ischemia. In addition, we observed an increased 
intracerebral deposition of fibrin(ogen) in VWF PLT chimeric mice compared with 
VWF KO mice indicating that local release of platelet VWF can promote 
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intracerebral thrombosis. It is tempting to speculate that platelets adhere to activated 
endothelium (or subendothelium) in the area of ischemia/reperfusion and upon 
activation, secrete their granular contents, including large amounts of UL-VWF. This 
may result in the formation of platelet-derived VWF strings that may even be more 
resistant to ADAMTS13 proteolysis.10,32 Similar to endothelial-derived VWF strings, 
VWF strings from platelets could recruit new platelets and inflammatory cells 
resulting in platelet/leukocyte plugs that block the microvasculature and contribute to 
the no-reflow phenomenon. Interestingly, such platelet derived-VWF strings have 
been shown in vitro.33 Future studies specifically addressing the inflammatory nature 
of platelet-derived VWF will definitely shed more light on its role in this thrombo-
inflammatory process. 
Despite in vitro data showing that purified platelet VWF has a lower affinity for 
GPIbα than plasma VWF,9 we found that platelet VWF mediates ischemic brain 
injury via a GPIb-dependent mechanism. This finding further supports the crucial 
importance of the VWF-GPIb axis in stroke.5-7,23,34 Although p0p/B is not cytotoxic to 
platelets,23 we observed a small decrease in platelet count in p0p/B-treated mice 
compared with the control group (657.4 ± 115.6 versus 895.7 ± 107.1, respectively; p 
< 0.01). This difference in platelet count can however not account for the observed 
difference in infarct size as 10% of normal platelet counts is already sufficient to 
induce full brain infarction following transient ischemic stroke.35  
 
In conclusion, our data shed an unexpected new light on the activity of platelet VWF 
and expand our insights on VWF-mediated mechanisms underlying ischemic stroke. 
This study further supports the idea that blocking the GPIb-VWF axis would be an 
interesting novel treatment strategy in stroke.  
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Figure legends 
 
Figure 1: Generation and characterization of chimeric mice that lack VWF in 
either megakaryocytes or endothelial cells. Mononuclear cells (MNC), isolated 
from donor WT (black) or VWF KO mice (white), were transplanted into lethally 
irradiated VWF KO or WT acceptor mice to generate (A) chimeric mice that have 
VWF only in platelets (VWF PLT) or (B) chimeric mice that specifically lack VWF 
in their platelets (VWF EC), respectively. (C) Relative amount of VWF-positive 
platelets detected in WT (n = 17), VWF KO  (n = 12), VWF PLT chimeric (n = 18) 
and VWF EC chimeric mice (n = 14). (D) VWF antigen levels (VWF:Ag) were 
determined in plasma samples from WT (n = 16), VWF KO (n =14), VWF PLT (n = 
21) chimeric, and VWF EC (n = 8) chimeric mice. (E) FVIII activity (FVIII:C) was 
determined in plasma samples from WT (n = 12), VWF KO (n =12), VWF PLT  
chimeric (n = 16), and VWF EC chimeric (n = 10) mice. Results are expressed as 
percentage of WT values. ***, P < 0.001; ns, not statistically significant. 
 
Figure 2: Plasma VWF is the major determinant to control bleeding in a tail clip 
bleeding assay. Five mm of the tail of WT (n = 15), VWF KO (n = 14), VWF PLT 
chimeric (n = 16), and VWF EC chimeric (n = 9) mice was removed. Subsequent tail 
bleeding in pre-warmed saline was monitored and the time needed to stop the 
bleeding was recorded. If bleeding did not end within the first 10 min, the experiment 
was ended with a recorded bleeding time of 600 s. ***, P < 0.001; ****, P < 0.0001; 
ns, not statistically significant. 
 
Figure 3: Plasma VWF but not platelet VWF determines thrombotic occlusion 
rates in a carotid artery thrombosis model. (A) The carotid artery of WT (n = 8), 
VWF KO (n = 5), VWF PLT chimeric (n = 8), and VWF EC chimeric (n = 6) mice 
was exposed and a local injury was generated by topical application of a filter paper 
saturated with 12% FeCl3. Carotid artery blood flow was monitored and the time 
needed to form an occlusive thrombus was recorded. If no occlusion occurred within 
50 min, the experiment was ended (time to occlusion of 50 min). (B) Carotid artery 
(CA) blood flow profiles of WT (black; n = 8), VWF KO (grey; n = 5), VWF PLT 
chimeric (dashed grey; n = 8), and VWF EC chimeric (dashed black; n = 6) mice 
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were recorded using a laser doppler flow monitor. **, P < 0.01; ***, P < 0.001; ns, 
not statistically significant. 
 
Figure 4: Platelet-derived VWF alone mediates ischemic stroke injury. Transient 
focal cerebral ischemia was induced by 60 min occlusion of the right middle cerebral 
artery, followed by 23 hours of reperfusion in WT (n = 12), VWF KO (n = 10), VWF 
PLT chimeric (n = 16), and VWF EC chimeric (n = 9) mice. (A) Representative TTC 
staining of 3 consecutive coronal brain sections 24 hours after induction of transient 
middle cerebral artery occlusion (tMCAO) are shown. White color indicates infarcted 
area, whereas a pink color shows unaffected brain tissue. (B) Brain infarct volumes as 
quantified by planimetric analysis 24 hours after tMCAO. (C) To exclude potential 
irradiation-mediated effects on cerebral injury, transient focal cerebral ischemia was 
induced in irradiated VWF KO mice transplanted with MNC derived from VWF KO 
mice (VWF KO + VWF KO PLTs). Planimetric analysis of brain infarct volumes 24 
hours after tMCAO in WT (n = 5), VWF KO (n = 7), and VWF KO + VWF KO PLTs 
chimeric mice (n = 7). *, P < 0.05; **, P < 0.01; ns, not statistically significant. 
 
 
Figure 5: Blockade of platelet GPIbα reduces platelet VWF-mediated ischemic 
stroke injury. Transient focal cerebral ischemia was induced by 60 min occlusion of 
the right middle cerebral artery, followed by 23 hours of reperfusion in non-treated 
WT (n = 6) and VWF KO (n = 5) mice, and VWF PLT chimeric mice treated with 
100 μg anti-GPIbα Fab (+ p0p/B; n = 8) or rat IgG Fab control (+ IgG Fab; n = 12). 
(A) Representative TTC stainings of 3 consecutive coronal brain sections 24 hours 
after tMCAO. White color indicates infarcted area, whereas a pink color shows 
unaffected brain tissue. (B) Brain infarct volumes as quantified by planimetric 
analysis 24 hours after tMCAO. **, P < 0.01; ns, not statistically significant. 
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Figure 6: Platelet-derived VWF contributes to ischemic brain injury by 
promoting intracerebral thrombosis. Transient focal cerebral ischemia was induced 
by 60 min occlusion of the right middle cerebral artery, followed by 23 hours of 
reperfusion in WT (n = 9), VWF KO (n = 8), non-treated VWF PLT chimeric (n = 7), 
anti-GPIbα Fab-treated VWF PLT chimeric (p0p/B, n = 5), and control IgG Fab-
treated VWF PLT chimeric (IgG Fab; n = 6) mice. Twenty-four hours after induction 
of ischemia, the amount of fibrin(ogen) in both the contralateral and ipsilateral 
hemisphere was determined by semi-quantitative Western blot. (A) Representative 
immunoblot showing accumulation of fibrin(ogen) in ipsi- (I) and contralateral (C) 
hemispheres. (B) Band intensities from A were quantified by densitometry. Each 
fibrin(ogen) density signal was first normalized to the corresponding actin density 
signal. The ratio of the normalized ipsilateral fibrin(ogen) density relative to the 
normalized contralateral fibrin band served as a measurement for relative fibrin(ogen) 
deposition (ratio IPSI/CONTRA). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not 
statistically significant. 
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VWF fosters ischemic stroke injury in mice
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